Our experiments with in vivo administration of the NLRP3 inhibitor, MCC950, show that the NLRP3 inhibition can block all of the early effects of a MASH diet and alcohol on the liver by preventing liver damage, steatosis, inflammation, neutrophil infiltration and NETs. The gene discussed is NLRP3; the disease is steatosis.